CIFF - Children's Investment Fund Foundation
Jan 2012 – Jan 2017
Kenya National Deworming Programme
Country
Kenya – Africa
To deworm millions of children through school-based drug distribution.
$12,864,553 Multi-Year Grant Value
Partners
Other funders
-
END Fund
The aim is to reduce Soil Transmitted Helminth (STH) prevalence in school aged children to below 4%.
Repeated rounds of deworming will take place over five years in the endemic areas of Kenya identified through disease mapping. The Kenyan Ministry of Education, Science and Technology and the Ministry of Public Health and Sanitation train teachers from each of the participating counties in how to deworm their pupils. The teachers then conduct mass drug administration within their schools with the oversight of community health workers.
Evidence Action provides technical advice on implementation and also advises the Kenyan Government on institutionalising the programme so that reductions in disease are sustained. All the drugs for both STH and Schistosomiasis are donated by GlaxoSmithKline and Merck KGaA respectively.
Impact
Our data showed a drop in STH prevalence from 33% to 16% over the first two years of the investment. During the same period Schistosomisasis haeatobium prevalence fell from 18% to 7.6%, and we aim to get below 1% over the course of the programme.
In the first year of funding, six million school aged children were treated, rising to 6.4 million in the second year. Halfway through the third year of implementation, more than three million children have received their deworming treatment and we are on schedule to meet our 5.5 million target.
The infographic below shows the change in prevalence rates - both before and immediately after treatments - over the three years of Kenya's National School-Based Deworming Programme, broken down by counties.
